Indian Pharma Market sees significant revival in March 2021, registers 10.3 percent growth: AIOCD-AWACS Report

A detailed analysis showed that Cardiac registered a monthly growth of 6.3% in March 2021, compared to 7.3% in February 2021. Anti-diabetic sales increased by only 0.3 per cent in March 2021, compared to 4.3 per cent in February 2021.

Anti-invectives, which had been growing at a negative rate of 11.3 per cent since the post-lockdown period, grew at an 8.5 per cent rate in March 2021.

The report further included that gastrointestinal drugs that grew at a faster rate of 21.6 per cent in March 2021 compared to 9.9 per cent in February 2021. Vitamins/minerals/nutrients, meanwhile, grew at a faster pace of 22.2 per cent in March 2021 compared to 8.6 per cent in February 2021.

Furthermore, pain/analgesics, neuro/CNS drugs, gynecological, antineoplastic hormones, and opthal/otologicals grew at 14.6%, 9.6%, 22.5%, 10.9%, and 13.1%, respectively.

The respiratory segment is still on a slow recovery path with a growth rate of-15.1% in March 2021 compared to-20.3% in February 2021.

According to the study, Cipla topped the list of 100 corporate with an 8.1% growth rate in March 21 without the Bonus unit, followed by Zydus Cadila with a 5.1% growth rate, Torrent with a 4.1% growth rate, and Intas with a 4% growth rate in March 21.

Also Read: ABCD Technologies Buys 66 Percent Stake In AWACS